Modern Care Journal

Published by: Kowsar

Serum Levels of Insulin-Like Growth Factor 1, Interlukin-6, Heat-Shock Proteins-27 and Heat-Shock Proteins-60 as Inflammatory Markers of Type 2 Diabetes: A Case-Control Study

Arash Ghorbani Abdi Saedabad 1 , Reyhane Rezaie 2 , Seyed Yoosef Javad Moosavi 1 , Gholamraza Anani Sarab 3 , Mohammad Malekaneh 3 and Reyhaneh Houshyar 3 , *
Authors Information
1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2 Mashhad University of Medical Sciences, Mashhad, Iran
3 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
Article information
  • Modern Care Journal: January 31, 2019, 16 (1); e80971
  • Published Online: February 12, 2019
  • Article Type: Research Article
  • Received: June 18, 2018
  • Revised: January 1, 2019
  • Accepted: January 14, 2019
  • DOI: 10.5812/modernc.80971

To Cite: Ghorbani Abdi Saedabad A , Rezaie R , Javad Moosavi S Y, Anani Sarab G , Malekaneh M , et al. Serum Levels of Insulin-Like Growth Factor 1, Interlukin-6, Heat-Shock Proteins-27 and Heat-Shock Proteins-60 as Inflammatory Markers of Type 2 Diabetes: A Case-Control Study, Mod Care J. 2019 ; 16(1):e80971. doi: 10.5812/modernc.80971.

Abstract
Copyright © 2019, Modern Care Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat Rev Drug Discov. 2014;13(6):465-76. doi: 10.1038/nrd4275. [PubMed: 24854413].
  • 2. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: A consensus on type 2 diabetes prevention. Diabet Med. 2007;24(5):451-63. doi: 10.1111/j.1464-5491.2007.02157.x. [PubMed: 17470191].
  • 3. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006;333(7566):475-80. doi: 10.1136/bmj.38922.650521.80. [PubMed: 16946335]. [PubMed Central: PMC1557968].
  • 4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. doi: 10.1001/jama.286.3.327. [PubMed: 11466099].
  • 5. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878-88. doi: 10.1016/j.bbamcr.2011.01.034. [PubMed: 21296109].
  • 6. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. Endocr Relat Cancer. 2012;19(5):F27-45. doi: 10.1530/ERC-11-0374. [PubMed: 22593429].
  • 7. Yuan J, Dunn P, Martinus RD. Detection of Hsp60 in saliva and serum from type 2 diabetic and non-diabetic control subjects. Cell Stress Chaperones. 2011;16(6):689-93. doi: 10.1007/s12192-011-0281-7. [PubMed: 21748374]. [PubMed Central: PMC3220386].
  • 8. Kishimoto T. IL-6: From its discovery to clinical applications. Int Immunol. 2010;22(5):347-52. doi: 10.1093/intimm/dxq030. [PubMed: 20410258].
  • 9. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538-42. doi: 10.1016/j.autrev.2009.01.012. [PubMed: 19189867].
  • 10. Mahgoub S, Youns M, Bassyouni A, Hassan Z. Serum levels of heat shock protein 27 as a potential marker of diabetic nephropathy in Egyptians with type 2 diabetes. J Appl Pharm Sci. 2012;2(11):14. doi: 10.7324/japs.2012.21104.
  • 11. Giffard RG, Han RQ, Emery JF, Duan M, Pittet JF. Regulation of apoptotic and inflammatory cell signaling in cerebral ischemia: The complex roles of heat shock protein 70. Anesthesiology. 2008;109(2):339-48. doi: 10.1097/ALN.0b013e31817f4ce0. [PubMed: 18648242]. [PubMed Central: PMC2561962].
  • 12. Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360(2):114-8. doi: 10.1016/j.canlet.2015.02.026. [PubMed: 25721081].
  • 13. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107. doi: 10.1038/nri2925. [PubMed: 21233852].
  • 14. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, et al. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 2005;82(3):675-84. quiz 714-5. doi: 10.1093/ajcn.82.3.675. [PubMed: 16155283]. [PubMed Central: PMC2563043].
  • 15. Drogan D, Schulze MB, Boeing H, Pischon T. Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: Results from the EPIC-potsdam study. Am J Epidemiol. 2016;183(6):553-60. doi: 10.1093/aje/kwv188. [PubMed: 26880678].
  • 16. Teppala S, Shankar A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care. 2010;33(10):2257-9. doi: 10.2337/dc10-0770. [PubMed: 20639451]. [PubMed Central: PMC2945170].
  • 17. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2008;18(2):166-73. doi: 10.1016/j.ghir.2007.08.004. [PubMed: 17904401]. [PubMed Central: PMC2492581].
  • 18. Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic S, Ostenson CG. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. Diabetologia. 2012;55(6):1668-78. doi: 10.1007/s00125-012-2529-x. [PubMed: 22426800].
  • 19. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, et al. The inflammatory status score including IL-6, TNF-alpha, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51(1):123-31. doi: 10.1007/s00592-013-0543-1. [PubMed: 24370923].
  • 20. Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann N Y Acad Sci. 2005;1053:74-83. doi: 10.1196/annals.1344.007. [PubMed: 16179510].
  • 21. Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): Biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7. doi: 10.1186/1755-1536-5-7. [PubMed: 22564335]. [PubMed Central: PMC3464729].
  • 22. Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: A novel circulating marker for diabetic neuropathy. Diabetes. 2008;57(7):1966-70. doi: 10.2337/db08-0009. [PubMed: 18390793]. [PubMed Central: PMC2453614].
  • 23. Hall L, Martinus RD. Hyperglycaemia and oxidative stress upregulate HSP60 and HSP70 expression in HeLa cells. Springerplus. 2013;2:431. doi: 10.1186/2193-1801-2-431. [PubMed: 24058891]. [PubMed Central: PMC3777022].
  • 24. Imatoh T, Sugie T, Miyazaki M, Tanihara S, Baba M, Momose Y, et al. Is heat shock protein 60 associated with type 2 diabetes mellitus? Diabetes Res Clin Pract. 2009;85(2):208-12. doi: 10.1016/j.diabres.2009.06.004. [PubMed: 19576649].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments